BioCentury | Aug 24, 2015
Company News

WuXi PharmaTech, New WuXi deal

...in WuXi. As of April 3, principal shareholders in WuXi included FIL Ltd. (10% stake), Schroder Investment Management...
BioCentury | Aug 15, 2015
Top Story

Investor group taking WuXi private in $3.3B deal

...in WuXi. As of April 3, principal shareholders in WuXi included FIL Ltd. (10% stake), Schroder Investment Management...
BioCentury | May 4, 2015
Company News

WuXi PharmaTech deal

...as of April 3. Principal shareholders listed in the filing included FIL Ltd. with 10%, Schroder Investment Management...
BioCentury | May 1, 2015
Company News

WuXi spikes on take-private proposal

...SEC Form 20-F filing. Principal shareholders listed in the filing included FIL Ltd. with 10%, Schroder Investment Management...
BioCentury | Oct 22, 2007
Finance

Ebb & Flow

Nektar (NKTR) was as surprised as anyone when Pfizer (PFE) announced last week that it would end further investment in Exubera inhaled insulin and return full worldwide rights to NKTR. The biotech, which developed and...
BioCentury | Oct 6, 2006
Financial News

Santhera raises EUR 10 million

...$12.7 million) in a series C round led by NGN Capital. New investors NeoMed Management; Schroder Investment Management...
BioCentury | Oct 2, 2006
Strategy

Racing to transform

...of the UCB shares they receive until after June 2010. SRZ's two largest minority investors, Schroder Investment Management...
BioCentury | May 27, 2006
Financial News

Sphere raises L6.2M

Diagnostic company Sphere ( Cambridge , U.K.) raised L6.2 million ($11.6 million) in a private round. New investors Oxford Capital; Fritas; and Schroders Investment Management joined existing investors Artemis ; Herald Ventures; Hotbed; and Generics Group. Sphere...
BioCentury | Mar 5, 2001
Finance

Ebb & Flow

While hot life science technologies come and go, VCs are reminding themselves that patience, combined with fundamental investment strategies like targeting big markets, sound management and a solid business plan never go out of style....
BioCentury | Mar 1, 2001
Financial News

Cellzome raises $31 million

Functional proteomics play Cellzome (Heidelberg, Germany) raised EUR 34 million in a private placement led by Index Ventures. Other investors included Sofinnova Ventures; Schroders Investment Management; Atlas Venture; Advent International; Heidelberg Innovation; and the company's...
Items per page:
1 - 10 of 11
BioCentury | Aug 24, 2015
Company News

WuXi PharmaTech, New WuXi deal

...in WuXi. As of April 3, principal shareholders in WuXi included FIL Ltd. (10% stake), Schroder Investment Management...
BioCentury | Aug 15, 2015
Top Story

Investor group taking WuXi private in $3.3B deal

...in WuXi. As of April 3, principal shareholders in WuXi included FIL Ltd. (10% stake), Schroder Investment Management...
BioCentury | May 4, 2015
Company News

WuXi PharmaTech deal

...as of April 3. Principal shareholders listed in the filing included FIL Ltd. with 10%, Schroder Investment Management...
BioCentury | May 1, 2015
Company News

WuXi spikes on take-private proposal

...SEC Form 20-F filing. Principal shareholders listed in the filing included FIL Ltd. with 10%, Schroder Investment Management...
BioCentury | Oct 22, 2007
Finance

Ebb & Flow

Nektar (NKTR) was as surprised as anyone when Pfizer (PFE) announced last week that it would end further investment in Exubera inhaled insulin and return full worldwide rights to NKTR. The biotech, which developed and...
BioCentury | Oct 6, 2006
Financial News

Santhera raises EUR 10 million

...$12.7 million) in a series C round led by NGN Capital. New investors NeoMed Management; Schroder Investment Management...
BioCentury | Oct 2, 2006
Strategy

Racing to transform

...of the UCB shares they receive until after June 2010. SRZ's two largest minority investors, Schroder Investment Management...
BioCentury | May 27, 2006
Financial News

Sphere raises L6.2M

Diagnostic company Sphere ( Cambridge , U.K.) raised L6.2 million ($11.6 million) in a private round. New investors Oxford Capital; Fritas; and Schroders Investment Management joined existing investors Artemis ; Herald Ventures; Hotbed; and Generics Group. Sphere...
BioCentury | Mar 5, 2001
Finance

Ebb & Flow

While hot life science technologies come and go, VCs are reminding themselves that patience, combined with fundamental investment strategies like targeting big markets, sound management and a solid business plan never go out of style....
BioCentury | Mar 1, 2001
Financial News

Cellzome raises $31 million

Functional proteomics play Cellzome (Heidelberg, Germany) raised EUR 34 million in a private placement led by Index Ventures. Other investors included Sofinnova Ventures; Schroders Investment Management; Atlas Venture; Advent International; Heidelberg Innovation; and the company's...
Items per page:
1 - 10 of 11